Ocular Therapeutix Inc. (NASDAQ:OCUL) saw a downside of -3.22% to $4.36 after subtracting -$0.15 on Monday. The 5-day average trading volume is 594,248 shares of the company’s common stock. It has gained $4.54 in the past week and touched a new high 2 times within the past 5 days. An average of 697,867 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,204,855.
OCUL’s 1-month performance is -10.74% or -$0.52 on its low of $4.22 reached on 08/02/23. The company’s shares have touched a 52-week low of $2.57 and high of $7.96, with the stock’s rally to the 52-week high happening on 06/12/23. YTD, OCUL has achieved 55.34% or $1.56 and has reached a new high 18 times. However, the current price is down -45.16% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
OCUL stock investors last saw insider trading activity on Jul 07.Ozden Rabia Gurses (Chief Medical Officer) most recently sold 832 shares at $4.93 per share on Jul 07. This transaction cost the insider $4,102. President and CEO, Mattessich Antony C., sold 19,669 shares at a price of $4.24 on Feb 06. Then, on Feb 06, Chief Financial Officer Notman Donald sold 6,476 shares at a price of $4.24 per share. This transaction amounted to $27,458.
Valuation Metrics
OCUL stock has a beta of 1.20. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 6.40 while the price-to-book (PB) in the most recent quarter is 33.58.
Ocular Therapeutix Inc.’s quick ratio for the period ended March 30 was 3.50, with the current ratio over the same period at 3.60. As well, the company’s long term debt to equity for the quarter ending March 30 was 5.64, while the total debt to equity was 5.64. In terms of profitability, the gross margin trailing 12 months is 91.40%. The trailing 12-month EBITDA margin is -148.65%. The firm’s gross profit as reported stood at $46.95 million against revenue of $51.49 million.
Earnings Surprise
For the quarterly period ending March 30 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 58.64% to -$30.32 million, while revenue of -$15.54 million was 48.75% off the previous quarter. Analysts expected OCUL to announce -$0.26 per share in earnings in its latest quarter, but it posted -$0.39, representing a -50.00% surprise. EBITDA for the quarter stood at more than -$22.07 million. OCUL stock balance sheet for the quarter ending March 30 shows that total liabilities totaled 118.86 million, with total debt at $64.61 million. Shareholders hold equity totaling $77.53 million.
Let’s look briefly at Ocular Therapeutix Inc. (OCUL) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 04 August was 41.70% to suggest the stock is trending Neutral, with historical volatility in this time period at 41.81%.
The stock’s 5-day moving average is $4.40, reflecting a -3.74% or -$0.17 change from its current price. OCUL is currently trading -13.29% above its 20-day SMA, -14.31% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -34.38% and SMA200 by+3.07%.
Stochastic %K and %D was 30.56% and 24.94% and the average true range (ATR) pointed at 0.22. The RSI (14) points at 40.74%, while the 14-day stochastic is at 22.90% with the period’s ATR at 0.25. The stock’s 9-day MACD Oscillator is pointing at 0.01 and -0.02 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Ocular Therapeutix Inc. (NASDAQ: OCUL), Robert W. Baird launched coverage with an Outperform rating. Analysts offering their rating for OCUL stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate OCUL as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 6 have offered a “buy” rating.
What is OCUL’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $9.00 and a high of $18.00, with their median price target at $13.00. Looking at these predictions, the average price target given by analysts is for Ocular Therapeutix Inc. (OCUL) stock is $13.13.
